Epistemology is the study of knowledge—what it is, where it comes from, and how we can use it. It concerns what we know, how we come to know anything, and under what conditions we can trust what we know. In science, these considerations are embedded in the very rules that guide inquiry. Operating quietly, they shape assumptions, methods, and standards of evidence that underpin entire belief systems. The science that gives rise to public health policy, particularly where vaccination is concerned, affects the very conditions of human well-being. Contrary to what many people might believe, however, knowledge in this area is not solid and fixed—it is continually shaped and reshaped. That's where the idea of "epistemological sculpting" comes in—it's a term adopted here to explain how evidence in vaccine science is not merely discovered but constructed.
In this article, epistemological sculpting refers to the deliberate shaping of what counts as valid knowledge or evidence as determined by institutions of authority—such as regulatory agencies, governments, courts, and academic bodies. It emphasizes the active, selective process through which certain forms of evidence are elevated, others are demoted, and the boundaries of “official” knowledge are carved to align with institutional priorities. It is a process where those who do the sculpting are not always conscious of it, even as they proceed with it reflexively, through habits and institutional routines that obscure the deeper choices being made. Herein lies the danger—when scholars and government leaders arrive at choices of evidence and policy through such routine procedures, their decisions rest on foundations never fully examined. While practical knowledge might not be achievable except through this sculpting process, the approach, especially in vaccine science, demands uncompromising rigor—in how evidence is gathered, in how faithfully methods produce the evidence, and in how all this is communicated. Vaccine science today transforms raw data into policy, but does it do so by embracing rigor of a caliber sufficient to justify current legal mandates for injection with products born of its foundational assumptions? There are competent, expert analyses suggesting that it does not.
Highly trained and credible professionals have documented a field-wide weakness in modern scientific research that has enabled flawed studies to shape public health policy. John Ioannidis, for example, in his landmark 2005 analysis, showed that most published findings are statistically more likely to be false than true, with studies in exploratory epidemiology yielding reliable results only about 20 percent of the time and those in discovery‑oriented genomics performing far worse at close to 0.1 percent of the time. Since Ioannidis’s analysis, organized teams of researchers attempting to replicate published studies have confirmed the scale of the problem. In science, reliability is measured by whether independent groups performing the same investigations arrive at the same results. Yet only 11 percent of landmark preclinical cancer studies were replicated, 39 percent of psychology studies were replicated, and large surveys of biomedical researchers have revealed that nearly three‑quarters of them believe that a replication crisis is underway. Taken together, these figures show that the erosion of rigor pervades multiple disciplines, which undermines the credibility of science itself as a foundation for policy.
[1] Baker, M. (2016). 1,500 Scientists Lift the Lid on Reproducibility, Nature, 533(7604), 452–454.
Summary available at: BioEd Online (2016). 1,500 Scientists Lift the Lid on Reproducibility.
Shows that nearly three‑quarters of surveyed scientists reported reproducibility problems, highlighting the scale of the crisis.
[2] Chen, Zhiwei (2025). The Reproducibility Crisis in Scientific Research: Causes and Solutions, University of Hong Kong.
Reports structural causes of the reproducibility crisis and proposes corrective strategies.
[3] Cobey, K. D., Ebrahimzadeh, S., Page, M. J., et al. (2024). Biomedical Researchers’ Perspectives on the Reproducibility of Research, PLOS Biology.
Reveals that biomedical researchers themselves see reproducibility as a major integrity challenge.
[4] Dagli, N., Haque, M., Kumar, S. (2024). The Replication Crisis: A Persistent Challenge in Biomedical Research, Semantic
Scholar.
Reports persistent replication failures in biomedical science and their implications for progress.
[5] House of Commons Science, Innovation and Technology Committee (UK) (2023). Reproducibility and Research Integrity:
Sixth Report of Session 2022–23, London: House of Commons.
Finds reproducibility concerns significant enough to warrant parliamentary investigation and policy reform.
[6] Ioannidis, J. P. A. (2005). Why Most Published Research Findings Are False, PLoS Medicine, 2(8): e124.
Shows that most published findings are statistically more likely to be false than true.
[7] Randall, David; Welse, Christopher (2018, updated 2024). The Irreproducibility Crisis of Modern Science: Causes, Consequences, and the Road to Reform, National Association of Scholars.
Shows that irreproducibility is systemic across disciplines and proposes reforms to restore rigor.
[8] Northwestern University Institute for Policy Research (2024). An Existential Crisis for Science, Evanston, IL: Northwestern
University.
Shows that reproducibility failures threaten science’s credibility and its role in society.
[9] Plackett, B. (2025). Amid White House Claims of a Research ‘Replication Crisis,’ Scientists Offer Solutions, Chemical &
Engineering News.
Reveals political recognition of the replication crisis and outlines proposed scientific remedies.
[10] Udesky, L. (2025). ‘Publish or Perish’ Culture Blamed for Reproducibility Crisis, Nature.
Finds that academic publishing pressures contribute directly to reproducibility failures.
[1 1] WorldMetrics (1 May 2025). Replication Statistics: Market Data Report 2025.
Shows quantitative replication rates across disciplines, underscoring the scale of the problem.
The broader crisis of scientific integrity unavoidably extends into the domain of vaccine clinical trials and regulatory oversight. Here, the same patterns of compromised evidence, opaque processes, and institutional capture shape decisions that affect millions of patients.
Trial Design Flaws
Vaccine trials have often relied on surrogate endpoints, such as antibody titers, rather than long‑term clinical outcomes. This substitution obscures whether vaccines achieve meaningful protection in real‑world settings. Safety has rarely been assessed cumulatively across the full CDC schedule of recommended doses, leaving unanswered questions about long‑term effects of repeated injections that stimulate the immune system. Many studies are too small to reliably detect less common outcomes, and they are presented by selectively reporting only favorable results, while downplaying or omitting unfavorable findings. This can allow adverse reactions to remain hidden or minimized.
Regulatory Opacity and Institutional Capture
Regulatory agencies have repeatedly depended on industry‑sponsored data, with little independent verification. FDA inspection reports, when disclosed at all, are routinely redacted, concealing irregularities from both journals and the public. Advisory committees such as ACIP (Advisory Committee on Immunization Practices) continue to recommend one‑size‑fits‑all schedules despite acknowledged gaps in evidence, reflecting institutional capture by the pharmaceutical industry rather than transparent science. Academic institutions compromise integrity by signing clinical-trial agreements that restrict data access and publication rights, which erodes scholarly independence to ensure vaccine‑sponsor control. This concealment of irregularities and erosion of independence leaves regulators without credibility and the public without adequate protection.
Suppression of Dissent and Ethical Consequences
Physicians who raise safety concerns are marginalized or sanctioned, while whistleblowers within NIH (National Institutes of Health) and other institutions face retaliation for exposing misconduct. Public health messaging is crafted by alliances among pharmaceutical companies, media, and technology platforms, reinforcing policy decisions that lack strong evidentiary support. The result is a degradation of medical ethics, where the priority of patient care is displaced by institutional and financial interests.
The crisis of integrity in vaccine science, as described above, has set the stage for reckless sculpting of uncertain knowledge into medical practice. Surrogate endpoints have replaced lived outcomes, opacity has shielded irregularities in the approval process, and suppression of dissent has replaced open dialogue. In such an environment, fragile conjecture poses as reliable knowledge, and the human body stands to become a casualty of it. The crisis, therefore, is the normalization of failure to respect the limits of what can be known, which perpetuates the ingrained habit of portraying uncertainty at those limits as if it were certainty.
[12] Dal-Ré, R.; Kesselheim, A. S.; Bourgeois, F. T. (2020). Increasing Access to FDA Inspection Reports on Irregularities and
Misconduct in Clinical Trials, JAMA, 323(19):1903–1904.
Highlights lack of transparency in FDA inspection reports, which are heavily redacted and rarely disclosed. Notes that hidden irregularities undermine trial integrity and calls for public availability to uphold scientific standards.
[13] Doshi, Peter (2013). Influenza: Marketing Vaccine by Marketing Disease, BMJ, 346:f3037.
Exposes how influenza vaccine policy rests on low‑quality studies, healthy-user bias, and surrogate endpoints (antibody
production rather than clinical outcomes). Argues that marketing vaccines depends on exaggerating influenza as a threat.
[14] Gupta, Ashwaria (2013). Fraud and Misconduct in Clinical Research: A Concern, Perspectives in Clinical Research, 4(2):144– 147.
Documents widespread misconduct in clinical research, including failures in investigational plans, record‑keeping, informed consent, adverse event reporting, and IRB notification/approval. Highlights vulnerability due to lack of harmonized frameworks.
[15] International Alliance of Physicians and Medical Scientists (2022).
Declares that COVID‑19 public health policies reflect corruption across pharmaceutical, insurance, healthcare, and financial institutions, reinforced by big tech, media, academia, and government. Argues that this corrupt alliance across institutions has compromised medical ethics and patient care.
[16] Kalderon, Nurit (2012). Whistleblowing, Misconduct, Fraud and Corruption at the NIH.
Exposes corruption within NIH grant administration, alleging diversion of funds to unauthorized personal projects. Highlights systemic misconduct in grant management.
[17] Padmapriya, T. (2014). Ethical Misconduct and Corruption in Medical Research, Journal of Education and Ethics in
Dentistry, 4(2):74–76.
Identifies multifactorial causes of misconduct, including pharmaceutical sponsorship, personal greed, and careerism. Notes flaws in randomized clinical trial design and undeclared adverse reactions in drug approval processes.
[18] Poutoglidou, Frideriki; Stavrakas, Marios; Tsetsos, Nikolaos; Poutoglidis, Alexandros; Tsentemeidou, Aikaterini; Fyrmpas, Georgios;
Karkos, Petros D. (2022). Fraud and Deceit in Medical Research: Insights and Current Perspectives, Voices in Bioethics 8.
Documents rising misconduct amid overwhelmed peer review. Details fabrication, falsification, and selective reporting, often tied to pharmaceutical sponsorship. Warns of public harm, wasted resources, and calls for criminalization of severe misconduct.
[19] Roberts, Ian; Ker, Katharine; Edwards, Phil; Beecher, Deirdre; Manno, Daniela; Sydenham, Emma (2015). The Knowledge System Underpinning Healthcare is Not Fit for Purpose and Must Change, BMJ, 350:h2463.
Argues that healthcare literature is saturated with low‑quality, underpowered trials. Notes systemic failures in peer review, meta‑analysis bias, and false positives in Cochrane reviews. Calls for a new evidence system to replace the flawed current one.
[20] Schulman, K. A.; Seils, D. M.; Timbie, J. W.; Sugarman, J.; Dame, L. A.; Weinfurt, K. P.; Mark, D. B.; Robert, M. (2002). A National Survey of Provisions in Clinical‑trial Agreements Between Medical Schools and Industry Sponsors, New England Journal of Medicine, 347(17):1335–1341.
Finds that academic institutions routinely compromise trial integrity by failing to adhere to ICMJE guidelines on design, data access, and publication rights. Urges reevaluation of contracting processes in clinical research.
[21] Seife, Charles (2015). Research Misconduct Identified by the US Food and Drug Administration: Out of Sight, Out of Mind, Out of the Peer‑Reviewed Literature, JAMA Internal Medicine, 175(4):567–577.
Finds FDA evidence of fraudulent data in numerous trials, yet journals rarely acknowledge it. Notes FDA’s failure to notify journals or the public, with redacted documents obscuring which trials are implicated.
[22] Smith, Richard (2021). Time to Assume that Health Research is Fraudulent Until Proven Otherwise?, The BMJ Opinion.
Warns that peer review cannot reliably detect fraud. Suggests systematic reviewers should assume studies are fraudulent until proven otherwise. Notes regulators lack resources and authority to address pervasive fraud.
[23] Thomas, Paul; Stoller, Kenneth; Stand for Health Freedom vs. Monarez, Susan P. (CDC Director) (2025). Complaint for Declaratory and Injunctive Relief, United States District Court, District of Columbia.
Challenges CDC and FDA for never testing cumulative vaccine schedules (72 doses). Criticizes ACIP’s one‑size‑fits‑all model and suppression of physicians who raise safety concerns. Notes IOM’s 2013 finding that no studies compare fully immunized vs. unimmunized children.
From the sources listed, it's clear that standards in medical research, teaching, communications, and government reflect how clinical-trial sponsors, regulators, educators, policy makers, publishers, business leaders and others have cooperated to sculpt practical knowledge in a way that disrespects human choice and bodily autonomy. The key fault is that this stakeholder collective enables and reinforces mandates where individuals are denied the opportunity to do their own cost/benefit analyses in light of actual uncertainty surrounding vaccine safety or effectiveness. Were it not for the denial of individual choice in the face of conflicting evidence, the seriousness of the matter would be far less grave.
Practical knowledge, in its most rigorous form, arises from a process of shaping various (even conflicting) sources of evidence with humility—respecting the limits of what can be known, and prioritizing human life, autonomy, and the integrity of inquiry itself. Profit motives. Personal gain. Institutional advancement. These forces shape knowledge into negligence, willful disregard, denial, and stubborn refusal to face what converging evidence reveals, forcing human beings to bear the full risks of undisclosed or misrepresented uncertainty. Nothing less than an overhaul of the public health perspective will repair what is now clearly a broken culture. Restoring integrity to science—to vaccine science in particular—demands that responsible leaders undertake the work that is necessary to correct data and procedures for applying it in ways that fully respect the body and mind of every person.
END
[Written with assistance from Microsoft Copilot AI]